Exploring how clonal hematopoiesis affects neurodegenerative diseases like Alzheimer's and ALS
Official title: Unraveling the Role of Clonal Hematopoiesis in Neurodegenerative Diseases
Funded at Icahn School of Medicine at Mount Sinai · NIH-11158439 · Data updated 2026-11-12
This study is looking at how a specific blood cell change called clonal hematopoiesis might affect the risk and progression of Alzheimer's disease and ALS, and it hopes to find new ways to prevent or treat these conditions, with the help of patients who can provide samples.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | September 18, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $350,001 |
| NIH project number | 1R56AG088669-01 |
| Project ID | NIH-11158439 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation include individuals diagnosed with Alzheimer's disease, Parkinson's disease, or amyotrophic lateral sclerosis.
✕Less likely to help
Patients with neurodegenerative diseases not related to clonal hematopoiesis may not benefit from this research.
What this research studies
This research investigates the role of clonal hematopoiesis (CH) in neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis. By analyzing high-throughput sequencing data, the study aims to understand how different types of CH may influence the risk and progression of these conditions. The research will also explore the underlying mechanisms of CH's effects on neurodegeneration, potentially leading to new insights into disease prevention and treatment. Patients may be involved in providing biological samples to help elucidate these relationships.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing or treating neurodegenerative diseases.
How similar studies have gone: Previous research has shown promising results regarding the protective effects of clonal hematopoiesis in Alzheimer's disease, suggesting potential for further exploration in this area.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Raj, Towfique — Icahn School of Medicine at Mount Sinai
- Study coordinator: Raj, Towfique
Related research
Other NIH-funded projects on the same topics.
-
Developing small molecules to treat TDP-43 related brain diseases
A potential new drug candidate (XL20) for diseases like Alzheimer’s and other dementias linked to TDP-43 protein problems is being developed and refined for people who live with these conditions.
-
Tau filament structure in Alzheimer’s and related dementias
Aims to map the detailed 3D shapes of tau protein filaments found in human brain diseases to help develop better diagnostics and treatments for Alzheimer’s-related dementias.
-
Targeting RNA Splicing Abnormalities in ALS/FTD
A research team aims to understand and correct abnormal RNA splicing in ALS and related brain diseases to help patients in the future.
-
Blood-brain barrier–friendly imaging agents for neurodegenerative diseases
A researcher team will test new imaging agents that can cross the brain barrier to help detect Alzheimer’s and related diseases earlier and more accurately.
-
Brain cell–derived EV markers to differentiate Alzheimer’s and related dementias
A Mayo Clinic team is testing brain-cell–specific tiny particles in blood to tell apart Alzheimer’s disease and similar dementias using advanced machine-learning analysis.
-
Fisetin approach to reduce vulnerability to community infections in aging veterans
A patient-friendly look at a study testing whether the natural compound fisetin can help aging Veterans stay healthier when they face common infections.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.